MyFinsight
Home
Blog
About
Proceeds from maturities
of marketable...
$117,175K
(-24.22%↓ Y/Y)
Net proceeds from
the exercise of...
$1,727K
(132.66%↑ Y/Y)
Net cash provided by
investing activities
$34,897K
(-7.63%↓ Y/Y)
Net cash provided by
(used in) financing...
$1,201K
(114.83%↑ Y/Y)
Canceled cashflow
$82,278K
Canceled cashflow
$526K
Net decrease in
cash, cash...
-$36,885K
(86.65%↑ Y/Y)
Canceled cashflow
$36,098K
Accounts receivable,
prepaid expenses, and...
-$8,873K
(-109.35%↓ Y/Y)
Non-cash stock-based
compensation
$8,089K
(-58.52%↓ Y/Y)
Depreciation and
amortization
$3,056K
(-80.78%↓ Y/Y)
Provision for excess and
obsolete inventory
$1,597K
(15.81%↑ Y/Y)
Other items, net
-$1,354K
(71.08%↑ Y/Y)
Purchases of marketable
securities
$81,690K
(-28.79%↓ Y/Y)
Capital expenditures,
including internal-use...
$588K
(-59.92%↓ Y/Y)
Finance lease payments
$526K
(-81.30%↓ Y/Y)
Net cash used in
operating activities
-$72,807K
(76.74%↑ Y/Y)
Canceled cashflow
$22,969K
Effect of exchange rate
on cash, cash...
-$176K
(-102.52%↓ Y/Y)
Net income (loss)
-$53,387K
(-108.54%↓ Y/Y)
Accounts payable,
accrued expenses, and...
-$37,092K
(86.49%↑ Y/Y)
Deferred revenue
-$4,713K
(99.23%↑ Y/Y)
Inventory
$318K
(-80.55%↓ Y/Y)
Back
Back
Cash Flow
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)
source: myfinsight.com